Monopar Therapeutics Inc.

MNPR | NASDAQ

Price Alert Chart Builder DCF Calculator

$95.72

-$0.75 (-0.78%)

At close: Sep 21, 2026, 4:00 PM ET

$95.45

-$0.27 (-0.28%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.78%

(1D)

Rating

Updated: Sep 18, 2026

14.8

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $641.23M

1D Range

94.95 98.03

52W Range

50.07 124.82

Valuation (TTM)

PE -40.91

PB 4.90

EV/EBITDA -27.41

Valuation (NTM)

Forward PE N/A

Forward PEG 2.75

Price Target $126

Cash Flow

FCF Yield -507.8%

SBC Adj. FCF Yield -731.2%

SBC Impact -44.0%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -59.2% | -32.7%

FCF 3Y | 5Y -148.9% | -98.8%

Returns

ROA -13.2%

ROE -13.1%

ROIC -16.9%

Financial Health

Net Cash

$134.3M

Current Ratio 33.56

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage,...

Sector Healthcare

Industry Biotechnology

Employees 22

IPO Date Dec 18, 2019

Website www.monopartx.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

$125

Upside

+30.59%

Buy (7)

Hold (1)

Sell (0)

Analyst Details ➞